p21Cip1 Confers resistance to imatinib in human chronic myeloid leukemia cells

Abstract Imatinib is a Bcr-Abl inhibitor used as first-line therapy of chronic myeloid leukemia (CML). p21Cip1 , initially described as a cell cycle inhibitor, also protects from apoptosis in some models. We describe that imatinib down-regulates p21Cip1 expression in CML cells. Using K562 cells with inducible p21 expression and transient transfections we found that p21 confers partial resistance to imatinib-induced apoptosis. This protection is not related to the G2-arrest provoked by p21, a decrease in the imatinib activity against Bcr-Abl or a cytoplasmic localization of p21. The results suggest an involvement of p21Cip1 in the response to imatinib in CML.